1. Home
  2. DRDB vs CADL Comparison

DRDB vs CADL Comparison

Compare DRDB & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DRDB
  • CADL
  • Stock Information
  • Founded
  • DRDB 2024
  • CADL 1999
  • Country
  • DRDB United States
  • CADL United States
  • Employees
  • DRDB N/A
  • CADL N/A
  • Industry
  • DRDB
  • CADL Biotechnology: Pharmaceutical Preparations
  • Sector
  • DRDB
  • CADL Health Care
  • Exchange
  • DRDB Nasdaq
  • CADL Nasdaq
  • Market Cap
  • DRDB 305.1M
  • CADL 306.4M
  • IPO Year
  • DRDB 2024
  • CADL 2021
  • Fundamental
  • Price
  • DRDB $10.00
  • CADL $8.09
  • Analyst Decision
  • DRDB
  • CADL Strong Buy
  • Analyst Count
  • DRDB 0
  • CADL 4
  • Target Price
  • DRDB N/A
  • CADL $21.00
  • AVG Volume (30 Days)
  • DRDB 69.4K
  • CADL 918.0K
  • Earning Date
  • DRDB 01-01-0001
  • CADL 03-13-2025
  • Dividend Yield
  • DRDB N/A
  • CADL N/A
  • EPS Growth
  • DRDB N/A
  • CADL N/A
  • EPS
  • DRDB N/A
  • CADL N/A
  • Revenue
  • DRDB N/A
  • CADL N/A
  • Revenue This Year
  • DRDB N/A
  • CADL N/A
  • Revenue Next Year
  • DRDB N/A
  • CADL N/A
  • P/E Ratio
  • DRDB N/A
  • CADL N/A
  • Revenue Growth
  • DRDB N/A
  • CADL N/A
  • 52 Week Low
  • DRDB $9.87
  • CADL $1.45
  • 52 Week High
  • DRDB $10.02
  • CADL $14.60
  • Technical
  • Relative Strength Index (RSI)
  • DRDB N/A
  • CADL 49.50
  • Support Level
  • DRDB N/A
  • CADL $7.85
  • Resistance Level
  • DRDB N/A
  • CADL $8.69
  • Average True Range (ATR)
  • DRDB 0.00
  • CADL 0.54
  • MACD
  • DRDB 0.00
  • CADL -0.02
  • Stochastic Oscillator
  • DRDB 0.00
  • CADL 54.55

About DRDB Roman DBDR Acquisition Corp. II Ordinary shares

Roman DBDR Acquisition Corp II is a blank check company.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: